301
T3D0300
Arsanilic acid
Arsanilic acid is an organoarsenic compound derived from orthoarsenic acid. It was once used as a human drug, but is now only found in veterinary medicine, where its use is controversial. (L386)
98-50-0
7389
C6H8AsNO3
216.972010
White powder.
232°C
Oral (L2) ; inhalation (L2); dermal (L2)
Arsenic and its metabolites disrupt ATP production through several mechanisms. At the level of the citric acid cycle, arsenic inhibits pyruvate dehydrogenase and by competing with phosphate it uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, mitochondrial respiration, and ATP synthesis. Hydrogen peroxide production is also increased, which might form reactive oxygen species and oxidative stress. Arsenic's carcinogenicity is influenced by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. The binding of other arsenic protein targets may also cause altered DNA repair enzyme activity, altered DNA methylation patterns and cell proliferation. (T1, A17)
Arsenic is absorbed mainly by inhalation or ingestion, as to a lesser extent, dermal exposure. It is then distributed throughout the body, where it is reduced into arsenite if necessary, then methylated into monomethylarsenic (MMA) and dimethylarsenic acid (DMA) by arsenite methyltransferase. Arsenic and its metabolites are primarily excreted in the urine. Arsenic is known to induce the metal-binding protein metallothionein, which decreases the toxic effects of arsenic and other metals by binding them and making them biologically inactive, as well as acting as an antioxidant. (L20)
LD50: 248 mg/kg (Intraperitoneal, Mouse) (T14)
LD50: 100 mg/kg (Intravenous, Mouse) (T14)
130 mg for an adult human. (T15)
3, not classifiable as to its carcinogenicity to humans. (L135)
Arsanilic acid is used to treate dysentery in swine. (L386)
Acute Oral: 0.005 mg/kg/day (L134)
Chronic Oral: 0.0003 mg/kg/day (L134)
Chronic Inhalation: 0.01 mg/m3 (L134)
Arsenic poisoning can lead to death from multi-system organ failure, probably from necrotic cell death, not apoptosis. Arsenic is also a known carcinogen, especially in skin, liver, bladder and lung cancers. (T1, L20)
Exposure to lower levels of arsenic can cause nausea and vomiting, decreased production of red and white blood cells, abnormal heart rhythm, damage to blood vessels, and a sensation of “pins and needles” in hands and feet. Breathing high levels of inorganic arsenic can give you a sore throat or irritated lungs. Arsenic also affects the brain, causing neurological disturbances such as headaches, confusion, and drowsiness. (A1)
Arsenic poisoning can be treated by chelation therapy, using chelating agents such as dimercaprol, EDTA or DMSA. Charcoal tablets may also be used for less severe cases. In addition, maintaining a diet high in sulfur helps eliminate arsenic from the body. (L20)
2009-03-06T18:58:28Z
2014-12-24T20:21:30Z
Metallothionein-2 (P02795)
Metallothionein-1G (P13640)
Metallothionein-1H (P80294)
Metallothionein-3 (P25713)
Metallothionein-1F (P04733)
Metallothionein-1E (P04732)
Metallothionein-1X (P80297)
Metallothionein-1A (P04731)
Metallothionein-1B (P07438)
Metallothionein-1M (Q8N339)
Metallothionein-4 (P47944)
Metallothionein-1L (Q93083)
Arsenite methyltransferase (Q9HBK9) (L92)
49477
Arsanilic acid
DB03006
true
Arsenite methyltransferase (Q9HBK9)
(L92)
Metallothionein-2 (P02795)
Metallothionein-1G (P13640)
Metallothionein-1H (P80294)
Metallothionein-3 (P25713)
Metallothionein-1F (P04733)
Metallothionein-1E (P04732)
Metallothionein-1X (P80297)
Metallothionein-1A (P04731)
Metallothionein-1B (P07438)
Metallothionein-1M (Q8N339)
Metallothionein-4 (P47944)
Metallothionein-1L (Q93083)
(L92)
NC1=CC=C(C=C1)[As](O)(O)=O
C6H8AsNO3
InChI=1S/C6H8AsNO3/c8-6-3-1-5(2-4-6)7(9,10)11/h1-4H,8H2,(H2,9,10,11)
InChIKey=XKNKHVGWJDPIRJ-UHFFFAOYSA-N
217.0542
216.972014544
Exogenous
Solid
CHEMBL351769
7111